Cite
Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data
MLA
Jacob D. Soumerai, et al. “Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Oct. 2022, p. S140. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........806b687b92e49192a95ee6ca3a3aefb9&authtype=sso&custid=ns315887.
APA
Jacob D. Soumerai, Stephen Opat, Chan Y. Cheah, Masa Lasica, Emma Verner, Peter J. Browett, Henry Chan, Eva González Barca, James Hilger, Yiqian Fang, David Simpson, & Constantine S. Tam. (2022). Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data. Clinical Lymphoma Myeloma and Leukemia, 22, S140.
Chicago
Jacob D. Soumerai, Stephen Opat, Chan Y. Cheah, Masa Lasica, Emma Verner, Peter J. Browett, Henry Chan, et al. 2022. “Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data.” Clinical Lymphoma Myeloma and Leukemia 22 (October): S140. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........806b687b92e49192a95ee6ca3a3aefb9&authtype=sso&custid=ns315887.